Overview of Entero-Vioform

Quick Facts

Property	Description
Active ingredient	Clioquinol (Iodochlorhydroxyquin)
Form	Tablets (historical), Cream, Ointment, Solution (topical)
Pharmacological class	Anti-infective; Antiprotozoal drug
General purpose	Controlling microbial or parasitic overgrowth
Origin	Synthetic (8-hydroxyquinoline derivative)

What is Entero-Vioform and its Active Ingredient, Clioquinol?

Entero-Vioform is the historical trade name for a medicinal preparation whose sole active ingredient is the synthetic compound Clioquinol, which is chemically known as iodochlorhydroxyquin. Clioquinol belongs to the family of 8-hydroxyquinoline derivatives, structurally placing it within the broader class of quinoline derivatives. This classification defines the drug’s origin as a manufactured, single-ingredient product, which contrasts it with modern, multi-component pharmaceutical blends. Clioquinol’s anti-infective properties have been a consistent focus in pharmacological studies, establishing its medical recognition as a compound with diverse antimicrobial activity.

The compound's structure provides the foundation for its function as an anti-infective. Its composition is formulated to ensure the delivery of the active substance, utilizing dry excipients for tablets or appropriate oleaginous or aqueous bases for topical preparations such as the well-known Vioform product.

Pharmacological Class and General Anti-infective Purpose

Clioquinol is categorized pharmacologically as an anti-infective and, more specifically, an antiprotozoal drug, intended to manage diseases caused by susceptible pathogenic microorganisms. Its general purpose is rooted in its ability to function as a bacteriostatic and antifungal agent. The underlying mechanism principle involves the compound acting as a metal chelator, a process where it binds to essential metal ions required by target pathogens, thereby disrupting their growth and reproduction. This action allows the medicine to control microbial overgrowth.

Historically, the drug’s primary internal purpose was as an amebicide for addressing parasitic gastrointestinal conditions. In contemporary applications, its utility is largely restricted to managing superficial skin infections and common dermatologic disorders caused by susceptible fungal or bacterial species.

Forms and Historical Context of Entero-Vioform

The Clioquinol preparation has been available in multiple dosage form(s), including historical oral preparations such as tablets, intended for the oral route of administration. Today, however, the drug’s identity is predominantly defined by its topical preparations, which include forms such as cream, ointment, and solution. This preference for the topical route is a defining characteristic of its current status, allowing the anti-infective effects to be concentrated on the skin surface to manage localized infections, as opposed to systemic treatment.

Therapeutic Uses of Entero-Vioform

What Entero-Vioform Treats: Main Uses and Benefits

The medication is relevant in contexts marked by increased discomfort for common, localized superficial infections of the skin caused by susceptible fungi and bacteria. The active ingredient is considered relevant for its anti-fungal and anti-bacterial properties in topical contexts. This includes conditions presenting with systemic or localized discomfort like athlete's foot (Tinea pedis), ringworm (Tinea corporis), and jock itch (Tinea cruris). It is commonly used when dermatologic disorders are associated with acute or disruptive episodes linked to a secondary microbial overgrowth.

Easing Pruritus, Redness, and Dermatological Discomfort

The key therapeutic benefit provides support that helps ease the overall symptom burden and helps address symptoms related to inflammatory or irritative states. It helps to reduce localized itching (pruritus), visible redness (erythema), and overall skin discomfort. This symptomatic relief contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Clioquinol is applied in addressing symptom clusters that may become intense or disruptive, providing support that helps ease the overall symptom burden for adults and older children.

Quick Fact: Support for Pruritus and Inflammation Symptoms

Property	Description
Primary Therapeutic Domain	Applied across domains where additional symptomatic support is needed.
Symptom Focus	Helps address symptoms related to physical discomfort, such as itching, redness, and general skin discomfort.
Relevant Context	Commonly used across conditions presenting with acute episodes involving localized infections.
Patient Benefit	Supports general well-being during symptomatic phases.

Regulatory References

NHS England Guidance on Clioquinol and Flumetasone Ear Drops

Eligibility and Restrictions for Use

Who Can and Cannot Use Entero-Vioform (Clioquinol)

The population eligibility for Entero-Vioform (Clioquinol) is strictly defined by regulatory label information, primarily concerning its topical forms.

Absolute Contraindications

Use of the medicine is contraindicated and must be avoided in patients with a known hypersensitivity to iodochlorhydroxyquin (Clioquinol), iodine, or any iodine-containing preparations. The medicine is also prohibited for individuals with specific skin infections, including most viral skin lesions (such as herpes simplex) and tuberculosis of the skin.

Age-Specific Restrictions

Age Group	Eligibility Status
Infants/Children (<2 years)	Not recommended for use.
Children (2 to 11 years)	Safety and effectiveness have not been established in pediatric patients below the age of 12 for certain formulations.
Adults (≥ 12 years)	Use is generally allowed in the absence of contraindications.

Conditional Use and Restrictions

Use requires caution and is restricted in patients with hepatic impairment or renal impairment due to the potential for increased systemic absorption and toxicity. Furthermore, application is not recommended on large surface areas, denuded skin, or for prolonged periods. During pregnancy, extensive or prolonged use is not recommended, and the medicine should only be used if clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Entero-Vioform (Clioquinol), particularly the topical formulation, is highly specific and does not include established interactions with other medicinal products. Official regulatory documentation defines the interaction pattern through a Drug–Laboratory Test Interference rather than conventional drug–drug conflicts.

Drug–Laboratory Test Interference

The most significant, formally documented interaction involves the drug's effect on diagnostic testing. As an iodine-containing compound, systemic absorption of the iodine component may occur with use, which can lead to interference with laboratory measurements.

Test Affected	Official Outcome
Thyroid Function Tests	May result in spuriously low or altered readings for tests like Protein-Bound Iodine (PBI) and radioactive iodine uptake.
PKU Test	May cause false-positive results on the ferric chloride test for phenylketonuria.

Interaction-Related Procedural Constraints

To prevent the iodine component from affecting the accuracy of diagnostic results, official regulatory information establishes a procedural constraint for testing. Affected Thyroid Function Tests must generally be deferred for a period of up to one month following the use of Clioquinol. Furthermore, the official profile confirms that interactions with food, alcohol, or herbal products are not established.

Mechanism of Action

Targeted Disruption of Pathogen Metal Homeostasis

The core action of Clioquinol is defined by its ability to function as a metal chelator and ionophore, binding to and transporting essential transition metal ions ( Zn^2+, Cu^2+, Fe^2+) across the microbial cell membrane. This mechanism immediately disrupts the metal balance within the pathogen's cytoplasm, leading to the functional failure of key metal-dependent enzymes required for survival and replication.

Pathway Blockade: Inhibition of Microbial Growth

The molecular action rapidly results in the functional inhibition of metalloenzymes critical to the pathogen's DNA synthesis and cellular respiration pathways. This simultaneous pathway blockade prevents the organism from multiplying or generating necessary energy, resulting in a bacteriostatic and fungistatic physiological consequence. This mechanism establishes a functional state characterized by the halting of cell multiplication at the site of action.

️ Mechanism Constraints and Static Effect Profile

The mechanism is intrinsically limited to an anti-proliferative or static effect, meaning it stops growth rather than actively causing rapid cellular death. This functional characteristic distinguishes it from mechanisms that induce rapid cellular death (cidal activity). The functional capacity of the mechanism is further constrained by the pathogen’s capacity to regulate metal efflux or sequester ions, which defines the conditions under which the drug's action is weaker or less effective.

Dosage and Administration Information

Official Administration Guidelines

The usage of the active ingredient, Clioquinol (Iodochlorhydroxyquin), involves precise administration routes, frequency, and application constraints.

Form	Approved Route	Standard Dosing Frequency
Cream/Ointment	Topical (Cutaneous)	Three to four times daily
Ear Drops	Otic (External Ear Canal)	Twice daily

For topical cutaneous preparations, the instruction is to apply a thin film or small quantity sufficient to cover the affected area. The application site should be cleaned and dried thoroughly before the medicine is applied to promote proper adherence and function. This form is intended for external use only, and the product label explicitly instructs against applying it with an occlusive dressing or bandage, as this may increase the potential for absorption.

For otic preparations, typically supplied in combination, the standard dosing regimen involves instilling 2 or 3 drops directly into the external auditory canal. Treatment courses are generally recommended to be short-term, often limited to a duration of 7 to 10 days, in established treatment protocols. The use of all formulations of the drug is generally not recommended in infants under two years of age.

A key procedural constraint to be noted is that the compound, due to its chemical nature, may stain skin, hair, and clothing a distinctive yellow color.

Recent Clinical Evidence

Entero-Vioform: Recent Clinical Evidence

Summary of Clinical Data

Entero-Vioform, which contains clioquinol (also known as iodochlorhydroxyquin), is primarily categorized as an antiprotozoal and antifungal agent. Its history of use has included the investigation of its role in treating and preventing certain diarrheal diseases, such as those caused by Entamoeba histolytica.

Key Findings in Phase III Trials

Formal, large-scale Phase III trials establishing current standards of efficacy and safety for systemic use are not widely available in contemporary medical literature. The drug's historical use as an oral antiprotozoal was largely discontinued or restricted in many countries due to safety concerns that arose from large-scale use in the mid-20th century.

Research has explored whether clioquinol could be associated with changes in disease progression in other areas, including neurodegenerative disorders and certain cancers, due to its properties as a zinc ionophore. These are investigational areas and are not currently established uses of the compound.

Safety and Contraindication Profile

Adverse event reports from past systemic use were primarily characterized by the development of Subacute Myelo-Optic Neuropathy (SMON) in some individuals, which led to the discontinuation of its oral formulation in several regions. This serious neurological condition involves damage to the spinal cord and optic nerve.

Currently, clioquinol is predominantly used in topical formulations (often combined with a corticosteroid) for treating fungal and bacterial skin infections. When used topically, adverse events are typically localized, such as skin irritation, burning, or discoloration at the application site. Systemic absorption remains a concern with topical use, and long-term use is generally advised against.

Frequently Asked Questions (FAQ)

Common questions about Entero-Vioform (FAQ)

Q: Is Entero-Vioform considered an antibiotic?

A: Official documents classify this medicine as an anti-infective and antiprotozoal drug. This classification indicates that it works against various microorganisms, including bacteria and fungi, primarily by stopping their growth, a mechanism described as bacteriostatic activity.

Q: Is Entero-Vioform the same as a probiotic?

A: Entero-Vioform is classified as an anti-infective agent intended to control the growth of pathogenic microbes. This function is fundamentally distinct from a probiotic, which is defined as a live microorganism intended to support overall gut health.

Q: What is the main difference between Entero-Vioform and other similar medicines for diarrhea?

A: The oral formulation of this medicine was historically used for diarrheal diseases. However, its systemic use was largely discontinued or restricted in many regions due to regulatory concerns regarding its association with the neurological condition, Subacute Myelo-Optic Neuropathy (SMON).

Q: Can Entero-Vioform cause nerve issues or tingling?

A: The serious neurological disorder historically linked to the systemic use of this drug is SMON. Official safety reports characterize SMON by sensory, motor, and visual disturbances, which are historically characterized by symptoms such as pain, numbness, or tingling.

Q: Can Entero-Vioform affect my vision or eyes?

A: The serious historical systemic safety concern, SMON, involves damage to the optic nerve, which is associated with visual disturbances. Furthermore, regulatory documents note that if the topical product comes into contact with the eyes, immediate rinsing with water is generally indicated.

Q: Does Entero-Vioform affect the results of any common medical tests?

A: The medicine is an iodine-containing compound, and systemic absorption of the iodine component may interfere with the results of certain laboratory tests. This interference may cause altered readings for Thyroid Function Tests and potentially lead to false-positive results on the test for phenylketonuria (PKU).

Q: Does Entero-Vioform affect the good bacteria in the gut?

A: The medicine functions as a bacteriostatic and antifungal agent intended to control microbial overgrowth. Its mechanism works by disrupting the metal balance within target pathogens.

Q: What is the purpose of the iodine component in Entero-Vioform?

A: The active ingredient is chemically known as iodochlorhydroxyquin, a halogenated compound. The presence of iodine and chlorine atoms in this chemical structure is noted to contribute to the compound's antimicrobial properties and overall biological activity.

Q: What is the full length of time people typically use Entero-Vioform for?

A: The medicine is generally intended for short-term use to minimize systemic absorption. Regulatory documentation indicates that for specific topical fungal infections, the duration of use is often limited to no longer than 7 days or as prescribed.

Q: Does Entero-Vioform interact with birth control pills?

A: Official regulatory information states that drug-to-drug interactions with other medicinal products are not established for this medicine.

Q: Can I drive or operate machinery while using Entero-Vioform?

A: The official safety profile notes that possible systemic adverse reactions (which occur with unknown frequency) may include dizziness and fainting. Regulatory documents note that these potential effects should be considered when planning activities such as driving or operating machinery.

Q: Is Entero-Vioform taken for prevention or only for treatment?

A: The anti-infective properties of the compound are utilized in topical applications where it can function as an antiseptic to clean and prevent infection. Official information therefore documents its use for both prevention and treatment.

Q: Can Entero-Vioform make symptoms worse initially?

A: The official list of adverse reactions for topical use notes rare instances of worsened skin irritation at the application site as a possible reaction.

Q: Is Entero-Vioform still being actively studied by researchers?

A: Research has explored investigational areas for the compound beyond its approved anti-infective use. Official documents mention studies looking into its potential role in conditions such as neurodegenerative disorders and certain cancers due to its specific chemical properties.

Q: What happens if I miss a dose of Entero-Vioform?

A: Regulatory-derived patient information addresses missed doses. It states that a missed dose should be applied as soon as it is remembered; however, if it is close to the time for the next scheduled dose, the patient information outlines that the missed dose should be skipped and the normal schedule resumed.

Q: Is Entero-Vioform available over-the-counter in some countries?

A: The final medicinal preparation is typically classified as a prescription-only (Rx) product in many major regulatory regions.

Q: What are the main risks associated with Entero-Vioform?

A: The main documented risks associated with this medicine include the historical systemic risk of Subacute Myelo-Optic Neuropathy (SMON), potential local adverse reactions like skin irritation, and the risk of increased systemic absorption with prolonged use or application over large or broken areas.

Q: Does using Entero-Vioform long-term cause any issues?

A: Regulatory documents note that prolonged use is generally not recommended for this medicine. The constraint is linked to the potential for increased systemic absorption and toxicity, which is why treatment duration is limited to short periods (e.g., no longer than 7 days for certain topical uses).

Q: Is there evidence that Entero-Vioform helps with traveler's diarrhea?

A: This drug was historically used and marketed for the prevention of traveler's diarrhea in its oral formulation. However, the oral formulations were subsequently restricted or discontinued in many countries due to significant safety concerns.

Q: What are the functional constraints of its mechanism (static effect profile) in simple terms?

A: The drug's mechanism is defined as primarily anti-proliferative or static. This means that its action works by stopping the growth and multiplication of the target organism, rather than actively causing the rapid death of the cells.

How should Entero-Vioform be stored and disposed of?

How to Store and Dispose of Entero-Vioform (Clioquinol)

Official regulatory information requires Entero-Vioform to be stored under specific environmental controls to maintain its stability.

Storage Requirements

Storage Condition	Requirement
Temperature	Store below 30 C and do not freeze.
Protection	Must be protected from light and kept in its tightly closed original container.
Child Safety	Mandatory instruction to keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Entero-Vioform must be disposed of in accordance with local requirements for pharmaceutical waste. The product should not be disposed of by pouring it down a sink or toilet unless explicitly instructed by the labeling. Consumers should utilize authorized drug take-back programs or follow official government guidelines for household disposal.

Classification	Example Adverse Reactions
Common	Pruritus (itching), local skin burning, or pain at the application site.
Rare	Worsened skin irritation, rash, or swelling.
Incidence Not Known	Systemic effects like diarrhea, nausea, vomiting, dizziness, or fainting (noted from historical systemic use profile).

Property	Description
Documented overdose presentations	The most severe documented syndrome is Subacute Myelo-Optic Neuropathy (SMON), characterized by abdominal symptoms, ascending numbness, motor disorders, and loss of visual acuity (blindness). Acute systemic exposure may also include fever, palpitations, and gait disturbance.
Physiological systems affected (as stated in label)	Nervous system (spinal cord, optic nerves, peripheral nerves) and Gastrointestinal system.
Dose-related or exposure-related factors (if applicable)	Risk of systemic toxicity is associated with prolonged or large-area application of topical forms.
Population-specific overdose notes (if applicable)	Children are noted to be more susceptible to systemic adverse effects due to increased absorption.
Emergency-response statements (as written in official documents)	Wipe out the excess topical product if too much is applied. Treatment is symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only)	Seek emergency medical treatment or call a poison control center immediately if a large quantity is swallowed or if severe symptoms such as passing out or trouble breathing occur.

Property	Description
Severity classification (as defined in official documents)	Severe / Life-threatening (based on outcomes of irreversible neurological sequelae and death in historical cases).
Regulatory basis (EMA / FDA / etc.)	Ministry of Health, Labour and Welfare (MHLW) of Japan (for SMON documentation) and national regulatory labels (for acute management).
Overdose-context constraints (as defined in official documents)	Management is restricted to symptomatic and supportive treatment; no specific antidote is listed.

Entero-Vioform